drugset
drugset / Trial / NCT04025957

A Study of SHR-1501 in Patients With Advanced Tumors

NCT04025957 ↗

Phase 1 Completed 19 enrolled Jiangsu HengRui Medicine Co., Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of SHR-1501 in patients with advanced malignancies .

Timeline

Start
2019-10-30
Primary completion
2022-07-31
Completion
2022-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-1501 Unknown — Subcutaneous

Indications

cancer